GLP-1 drugs from Novo, Lilly go head to head in clinical study: We explore the findings and their impact on the broader weight loss drug market.
OpenAI’s CEO, Arianna Huffington launch startup: It may take some time for the new venture’s AI-based personalized health coach to realize its full potential. Here’s why.
Strengthened features for user data analysis could help increase Oura’s adoption in the wearables market and justify its cost.
Samsung unveils smartwatch feature that isn’t available on Apple Watch: Here’s how the new health-tracking feature works and why the specter of Apple looms large for Samsung in the health wearables space.
Our top 5 articles in H1 2024: Consumers’ media habits, patients’ healthcare spending, and Big Pharma drew the most attention from our digital health audience.
What do doctors think of at-home diagnostic tests? We explore what it will take for the market to evolve even further.
FTC investigates Teva over drug patents: The drugmaker isn’t going down without a fight. Market competition and Rx prices are on the line.
Health insurers are covering fewer prescription drugs: We unpack new Rx spending data from GoodRx and explore what it means for patients.
Gen Xers and millennials are worried about the future of Medicare: But they aren’t educated on what the program provides. We explore the opportunity for marketers.
Report raises questions about Hims & Hers’ new GLP-1 offering: We examine how the chaotic weight-loss drug market has become a slippery slope for some players in the space.
How health plans can improve members’ satisfaction levels: It primarily comes down to easier access to care and lower costs.
TikTok health advice comes with a price: Here’s the danger lurking behind Gen Z’s practice of turning to TikTok for health advice and some recent developments that suggest help is on the way for younger social media users.
US adults report mixed comfort with healthcare AI: We unpack recent survey results and explore a potential pathway healthcare providers and AI developers can follow to address consumers’ AI-related concerns.
How pharma companies can build trust with physicians: Corporate brand messaging won’t drive doctors to prescribe meds. Docs want data on medications and information that will help them care for patients.
The state of digital health funding: A recent $200 million funding haul and IPO plans signal it may not be all doom and gloom in the post-pandemic era.
Teva launches generic GLP-1 in the US: Competition in the space is heating up. And with more generic drugs on the market, we think brand-name GLP-1 prices will be forced down.
Amazon Clinic gets rolled into One Medical: We explore what it means for Amazon’s broader healthcare strategy.
Medicare rebate program lowers prices on 64 prescription drugs: The Biden administration wants to improve its election odds by touting efforts that drive Rx savings for consumers.
Walgreens plans US store closures, reduces stake in VillageMD: It’s the latest domino to fall in the US’ embattled retail health space. We predict who could be next.
Patients aren’t sold on the safety of GLP-1s: It’s why most consumers prefer adopting healthy habits to taking medication for a health condition. We explore what this means for healthcare/pharma brands and marketers.